Pacific Biosciences of California (PACB) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 2.44
(+103.13%)
Based on the Pacific Biosciences of California stock forecast from 8 analysts, the average analyst target price for Pacific Biosciences of California is USD 2.44 over the next 12 months. Pacific Biosciences of California’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Pacific Biosciences of California is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Pacific Biosciences of California’s stock price was USD 1.20. Pacific Biosciences of California’s stock price has changed by -17.24% over the past week, -1.64% over the past month and -14.29% over the last year.
No recent analyst target price found for Pacific Biosciences of California
No recent average analyst rating found for Pacific Biosciences of California
Company Overview Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. Read Less
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and ...Read More
Frequently Asked Questions About Pacific Biosciences of California (PACB) Stock
Based on ratings from 8 analysts Pacific Biosciences of California's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and 7 hold ratings.
Unfortunately we do not have enough data on PACB's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for PACB is USD 2.44 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 1.5.
PACB stock's Price/Earning ratio is 194.47.
Our analysis grades PACB stock's Price / Earning ratio at F. This means that PACB stock's Price/Earning ratio is above 86% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this PACB may be a overvalued for its sector.
The last closing price of PACB's stock was USD 1.20.
The most recent market capitalization for PACB is USD 0.37B.
Based on targets from 8 analysts, the average taret price for PACB is projected at USD 2.44 over the next 12 months.
This means that PACB's stock price may go up by +103.13% over the next 12 months.
We can't find any ETFs which contains Pacific Biosciences of California's stock.
As per our most recent records Pacific Biosciences of California has 575 Employees.
Pacific Biosciences of California's registered address is 1305 O?Brien Drive, Menlo Park, CA, United States, 94025.
You can get more information about it from Pacific Biosciences of California's website at https://www.pacb.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Pacific Biosciences of California (PACB) Stock
Based on ratings from 8 analysts Pacific Biosciences of California's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and 7 hold ratings.
Unfortunately we do not have enough data on PACB's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for PACB is USD 2.44 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 1.5.
PACB stock's Price/Earning ratio is 194.47.
Our analysis grades PACB stock's Price / Earning ratio at F. This means that PACB stock's Price/Earning ratio is above 86% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this PACB may be a overvalued for its sector.
The last closing price of PACB's stock was USD 1.20.
The most recent market capitalization for PACB is USD 0.37B.
Based on targets from 8 analysts, the average taret price for PACB is projected at USD 2.44 over the next 12 months.
This means that PACB's stock price may go up by +103.13% over the next 12 months.
We can't find any ETFs which contains Pacific Biosciences of California's stock.
As per our most recent records Pacific Biosciences of California has 575 Employees.
Pacific Biosciences of California's registered address is 1305 O?Brien Drive, Menlo Park, CA, United States, 94025.
You can get more information about it from Pacific Biosciences of California's website at https://www.pacb.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PACB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
